内城哮喘协会 3 (ICAC3)-猫眼课题宝

内城哮喘协会 3 (ICAC3)

批准号：

8903803

负责人：

William W. Busse

金额：

$1212.54万

依托单位：

UNIVERSITY OF WISCONSIN-MADISON

依托单位国家：

美国

项目类别：

财政年份：

2014

资助国家：

美国

项目状态：

已结题

起止时间：

2014-08-05 至 2021-07-31

来源：

https://reporter.nih.gov/project-details/8903803

关键词：

16 year old Address Adolescence Adolescent Allergen Immunotherapy Allergens Allergic Anti-Cholinergics Asthma Bacteria Biological Birth Caring Cells Characteristics Child Childhood Childhood Asthma Clinical Cohort Studies Collaborations Complex Development Dictyoptera Disease Disease Progression Disease remission Environment Environmental Exposure Environmental Risk Factor Epidemic Epigenetic Process Epitopes Exposure to Goals Grant Guidelines House Dust Household IgE Immune Immune response Immunobiology Immunologics Immunotherapy Incidence Interleukin-5 Intervention Lead Leptin Life Link Mediating Metabolic Microbe Multicenter Studies Muscarinic Antagonists Obesity Outcome Participant Peripheral Blood Eosinophilia Phenotype Plasma Population Prevalence Prevention Process Protocols documentation Recurrence Research Design Respiratory Tract Infections Risk Risk Factors Role School-Age Population Severities Shapes Source Stimulus Systems Biology T cell response T-Lymphocyte Testing Wheezing Work airborne allergen allergic airway disease asthmatic asthmatic patient base cockroach allergen cohort design disorder control early childhood gastrointestinal genetic risk factor high risk immunoregulation improved in utero infancy inner city mepolizumab microbial microbiome mouse allergen omalizumab prevent respiratory response subcutaneous therapy design

项目摘要

项目成果

William W. Busse的其他基金

相似基金

相关文献

中文摘要

翻译

简介（由申请人提供）：廉署的目标是进一步发展蟑螂过敏原免疫疗法及考虑新的过敏原免疫疗法；比如老鼠的过敏原；开发和执行针对市中心哮喘表型的临床和机制研究，以及旨在预防哮喘发病率或其进展的干预措施。此外，URECA出生队列研究将继续进行到拨款结束，届时参与者将在14至16岁之间，目的是提供关于儿童期晚期和青春期发病哮喘的免疫学基础信息，以及同一时期哮喘的缓解情况。

英文摘要

DESCRIPTION (provided by applicant): ICAC's goal is to include further development of cockroach allergen immunotherapy and consideration of new allergen immunotherapies; for example to mouse allergens; the development and execution of clinical and mechanistic studies targeted to inner-city asthma phenotypes, and interventions designed to prevent the incidence of asthma or its progression. In addition, the URECA birth cohort study will be continued to the end of the grant, when the participants will range from 14 to 16 years of age, with the goal to provide information on the immunologic basis of late childhood and adolescence-onset asthma, as well as the remission of asthma during the same years.

期刊论文(0)

专著(0)

科研奖励(0)

会议论文